Q4 beat and long-term guidance upgrade welcomed by the markets
06/02/25 -"The Q4 results exceeded the street’s expectations, while the 2025 outlook was in line with consensus estimates. Moreover, the firm raised its longer-term sales ambition, despite key HIV patent ..."
Pages
62
Language
English
Published on
06/02/25
You may also be interested by these reports :
19/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...
12/12/25
Eli Lilly’s Retatrutide grabbed headlines with c.29% weight-loss efficacy in late-stage trials for obese patients who also had knee osteoarthritis. ...
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...